René Belder

6.4k total citations · 1 hit paper
13 papers, 4.6k citations indexed

About

René Belder is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, René Belder has authored 13 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 5 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Economics and Econometrics. Recurrent topics in René Belder's work include Lipoproteins and Cardiovascular Health (10 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers). René Belder is often cited by papers focused on Lipoproteins and Cardiovascular Health (10 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers). René Belder collaborates with scholars based in United States, Germany and Netherlands. René Belder's co-authors include Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald, Marc A. Pfeffer, Allan M. Skene, Jean L. Rouleau, Daniel J. Rader, Steven Joyal, Kristiina Nyyssönen and Jong-Soon Park and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American Statistical Association.

In The Last Decade

René Belder

13 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes

2004 3.4k citations Christopher P. Cannon, Eugene Braunwald et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
René Belder United States	9	3.4k	1.6k	1.3k	1.1k	538	13	4.6k
David D. Waters United States	22	3.5k 1.0×	1.4k 0.9×	1.7k 1.3×	1.1k 1.0×	662 1.2×	37	4.8k
S. Féasson France	4	3.7k 1.1×	1.6k 1.0×	1.5k 1.2×	1.2k 1.1×	631 1.2×	6	5.4k
A. Tonkin Australia	4	3.3k 1.0×	1.3k 0.8×	1.3k 1.0×	1.2k 1.1×	559 1.0×	9	4.2k
Jennifer A. White United States	29	3.9k 1.1×	2.0k 1.3×	1.6k 1.2×	1.4k 1.2×	626 1.2×	59	5.6k
Gabriele Riccardi Italy	14	3.0k 0.9×	1.5k 0.9×	1.6k 1.2×	972 0.9×	583 1.1×	20	4.5k
Steven Joyal United States	9	2.9k 0.9×	1.2k 0.8×	1.2k 0.9×	1.0k 0.9×	466 0.9×	15	4.0k
T. Sourjina Australia	8	3.6k 1.1×	1.3k 0.8×	1.6k 1.2×	1.3k 1.2×	929 1.7×	9	5.3k
C Pollicino Australia	6	3.5k 1.0×	1.3k 0.8×	1.6k 1.2×	1.3k 1.2×	852 1.6×	9	5.1k
Valerie A. Cain United States	19	3.0k 0.9×	1.0k 0.6×	1.6k 1.2×	792 0.7×	579 1.1×	33	4.2k
Christina Reith United Kingdom	15	3.8k 1.1×	1.3k 0.8×	1.6k 1.2×	1.5k 1.3×	702 1.3×	30	5.4k

Countries citing papers authored by René Belder

Since Specialization

Citations

This map shows the geographic impact of René Belder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by René Belder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites René Belder more than expected).

Fields of papers citing papers by René Belder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by René Belder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by René Belder. The network helps show where René Belder may publish in the future.

Co-authorship network of co-authors of René Belder

This figure shows the co-authorship network connecting the top 25 collaborators of René Belder. A scholar is included among the top collaborators of René Belder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with René Belder. René Belder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Belder, René, et al.. (2018). Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes. Current Medical Research and Opinion. 35(6). 1081–1089. 3 indexed citations

Neutel, Joel M., et al.. (2008). Abstract 4420: Results of A Double Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of PS433540 in Human Subjects with Hypertension. Circulation. 118(suppl_18). 4 indexed citations

Lewis, James H., et al.. (2007). Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 46(5). 1453–1463. 231 indexed citations

Lewis, James H., et al.. (2006). Is the Lipid Reduction Seen with High-Dose Pravastatin (Prava) Associated with a Fall in ALT Values in Hypercholesterolemic Pts with NAFLD? Results from a Prospective, Randomized Double-Blind, Placebo (PBO)-Controlled Trial. The American Journal of Gastroenterology. 101. S158–S159. 2 indexed citations

Kendall, David M., Cindy J. Rubin, Pharis Mohideen, et al.. (2006). Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy. Diabetes Care. 29(5). 1016–1023. 88 indexed citations

Grooth, Greetje J. de, Kim E. Zerba, Shu‐Pang Huang, et al.. (2004). The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome. Journal of the American College of Cardiology. 43(5). 854–857. 52 indexed citations

Hennekens, Charles H., Frank M. Sacks, Andrew Tonkin, et al.. (2004). Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease. Archives of Internal Medicine. 164(1). 40–40. 82 indexed citations

Cannon, Christopher P., Eugene Braunwald, Carolyn H. McCabe, et al.. (2004). Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine. 350(15). 1495–1504. 3449 indexed citations breakdown →

Berry, Scott, et al.. (2004). Bayesian Survival Analysis With Nonproportional Hazards. Journal of the American Statistical Association. 99(465). 36–44. 31 indexed citations

10.

Cannon, Christopher P., Eugene Braunwald, Carolyn H. McCabe, et al.. (2004). Comparison of Intensive and Moderate Lipid Lowering With Statins After Acute Coronary Symptoms. Obstetrical & Gynecological Survey. 59(7). 522–524. 104 indexed citations

11.

Hennekens, Charles H., Frank M. Sacks, Andrew Tonkin, et al.. (2003). Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: Randomized and observational comparisons of secondary prevention trials and their meta-analysis. Journal of the American College of Cardiology. 41(6). 526–526. 6 indexed citations

12.

Cannon, Christopher P., Carolyn H. McCabe, René Belder, Jeanne D. Breen, & Eugene Braunwald. (2002). Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)—TIMI 22 trial. The American Journal of Cardiology. 89(7). 860–861. 92 indexed citations

13.

Salonen, Riitta, et al.. (1995). Kuopio Atherosclerosis Prevention Study (KAPS). Circulation. 92(7). 1758–1764. 437 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact